Jade Biosciences, Inc. JBIO

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the best biotech stocks on this list. TheFly reported on June 15 that UBS initiated coverage of JBIO with a Buy rating and a $45 price target. The firm highlighted JADE101 as the company’s […]

SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026. “We are pleased to welcome Dr. Eisner to the board,” said Tom Frohlich, Chief Executive Officer of Jade Biosciences. “Mark’s bioph

SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting th

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, i

~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect observed to be faster, deeper, and more durable than with first-generation anti-APRIL or dual APRIL/BAFF agentsJADE101 was well-tolerated across all evaluated dosesPhase 2 clinical trial in patients with IgA nephropathy underway, with interim clinical data expected in 2027Phase 3 registrational tri

SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101. The data are expected to define the dosing strategy and furt

Jade Biosciences stock overview following recent trading performance Jade Biosciences (JBIO) has drawn attention after a recent stretch of trading that left the stock down 3.1% on the day and 11.2% over the past week, sharpening interest in its recent gains over the past 3 months and year. See our latest analysis for Jade Biosciences. Despite the weak recent share price returns, with the stock down 21.2% over 30 days, Jade Biosciences still shows strong momentum over longer periods. This is...

Interim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the first participant has been dosed in JUNIPER, the Company’s Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy (IgAN). JADE101 is designed

Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin in the second quarter of 2026; interim data expected in 2027 Phase 1 study of JADE201, a half-life extended afucosylated anti-BAFF-R antibody, expected to begin in the second quarter of 2026; interim data expected in 2027 Phase 1 clinical trial for JADE301 remains on track to begin in the first hal